Search

 

Top
Residency Application
Directory
SCFI Members Login
Accredited by PDS

The Skin and Cancer Foundation, Inc. (SCFI) is one of the eleven residency training institutions accredited by the Philippine Dermatological Society (PDS). It is the second residency training program to be approved by the PDS. The PDS, in turn, is the only specialty society for Dermatology accredited by the Philippine Medical Association (PMA) and the Philippine College of Physicians (PCP).

 

« Residency Applications for 2023 BATCH 2 is extended! | Main | Residency Applications for 2023 BATCH 2 is now open! »
Thursday
Oct272022

World Psoriasis Day 2022: STOP THE STIGMA NOW!

DateThursday, October 27, 2022 at 11:31PM
Last October 23, 2022, the Skin and Cancer Foundation Inc. in association with the Philippine Dermatological Society and Psoriasis Philippines, celebrated World Psoriasis Day 2022 entitled “STOP THE STIGMA NOW!: United we tackle mental health”. The day started with a Fun Walk along Roxas Boulevard, followed by a program at the San Andres Sports Complex Covered Court. It was a great way to increase awareness to Psoriasis  and show support to all our dear patients battling this disease. 
Psoriasis may have many challenges both physically and mentally. Many people with psoriatic disease continue to face unmet needs and discrimination. But united, we can help stop the stigma.

 



AuthorSCFI 2022 | CommentPost a Comment | Reference2 References |

References (2)

References allow you to track sources for this article, as well as articles that were written in response to this article.

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
Post:
 
Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>

Notify me of follow-up comments via email.